Dr. Robert C. Wang, M.D.
Ophthalmology (Ophthalmology Physician)
- Medicare participating
At a glance
- Medical school
- Ohio State University College of Medicine (1996)
- Years since graduation
- 30
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 1,133
Licensed in Texas since 2002, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1996Medical school: Ohio State University College of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Ophthalmology Physician primary
TX license L4795 (first issued 2002; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Texas Health Presbyterian Hospital Dallas Dallas, TX
Medical groups
- Texas Retina Associates (18 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,133
- Services billed
- 66,748
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Injection, faricimab-svoa, 0.1 mg | 63,555 | 263 |
| Imaging of retina | 2,836 | 1,081 |
| Injection of drug into eye | 1,537 | 443 |
| Established patient complete exam of visual system | 1,024 | 719 |
| Injection, aflibercept, 1 mg | 989 | 130 |
| Injection, triamcinolone acetonide (xipere), 1 mg | 976 | 20 |
| Injection, pegcetacoplan, intravitreal, 1 mg | 840 | 25 |
| Injection, dexamethasone, intravitreal implant, 0.1 mg | 743 | 37 |
| Established patient problem focused exam of visual system | 658 | 448 |
| Established patient office or other outpatient visit, 20-29 minutes | 456 | 333 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisolone Acetate Other prescribers in Dallas, TX | 208 |
| Difluprednate | 195 |
| Prednisone Other prescribers in Dallas, TX | 190 |
| Neomycin-Polymyxin-Dexameth (neomycin/polymyxin b/dexametha) Other prescribers in Dallas, TX | 173 |
| Tramadol Hcl Other prescribers in Dallas, TX | 159 |
| Humira(Cf) Pen (adalimumab) Other prescribers in Dallas, TX | 148 |
| Methotrexate (methotrexate sodium) Other prescribers in Dallas, TX | 103 |
| Latanoprost Other prescribers in Dallas, TX | 102 |
| Dorzolamide-Timolol (dorzolamide hcl/timolol maleat) Other prescribers in Dallas, TX | 95 |
| Brimonidine Tartrate Other prescribers in Dallas, TX | 79 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 11 companies reported 63 payments worth $20,254 in total to this clinician.
| Ani Pharmaceuticals, Inc. | $11,120 |
|---|---|
| Bausch & Lomb Americas Inc. | $3,682 |
| Harrow Eye, LLC | $3,315 |
| Genentech, Inc. | $705 |
| Regeneron Healthcare Solutions, Inc. | $567 |
| Mallinckrodt Hospital Products Inc. | $349 |
| Apellis Pharmaceuticals, Inc. | $242 |
| AbbVie Inc. | $133 |
| Honoraria | $11,025 |
|---|---|
| Consulting Fee | $6,505 |
| Food and Beverage | $2,209 |
| Speaking at a medical education program | $500 |
| Education | $14.70 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Ani Pharmaceuticals, Inc. Sep 2, 2025 | Honoraria PURIFIED CORTROPHIN GEL · Treatment of certain chronic autoimmune disorders including acute exacerbations | $9,450 |
| Bausch & Lomb Americas Inc. Aug 18, 2025 | Consulting Fee XIPERE · Ophthalmology | $3,000 |
| Harrow Eye, LLC Jun 26, 2025 | Consulting Fee IHEEZO; TRIESENCE · OPTOMETRY | $2,800 |
| Ani Pharmaceuticals, Inc. Nov 20, 2025 | Honoraria YUTIQ · Treatment of chronic non-infectious uveitis affecting the posterior segment of t | $1,575 |
| Genentech, Inc. Jul 16, 2025 | Consulting Fee Vabysmo; Susvimo · Immunology and Ophthalmology | $705 |
| Bausch & Lomb Americas Inc. Jul 17, 2025 | Speaking at a medical education program XIPERE · Ophthalmology | $500 |
| Ani Pharmaceuticals, Inc. Aug 19, 2025 | Education PURIFIED CORTROPHIN GEL · Treatment of certain chronic autoimmune disorders including acute exacerbations · in-kind | $14.70 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.